関連する実験動画
Updated: Jul 24, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
まとめ
グルカゴンの抑制は,糖尿病の犬の高血糖症を大幅に軽減し,グルカゴンは重度の糖尿病に不可欠であることを示しています. この発見は,グルカゴンをターゲットにすることで,糖尿病の治療とグルコースの調節を改善できることを示唆しています.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック研究
- 糖尿病の病理生理学 糖尿病の病理生理学
背景:
- 糖尿病における重度の高血糖症は,臨床的に重大な懸念事項である.
- 糖尿病性高血糖症におけるインスリン不足とグルカゴン過剰の相互作用は複雑である.
- 以前の研究で,グルカゴンが糖尿病の合併症の発生に関与していることが明らかになった.
研究 の 目的:
- インスリン欠乏状態における重度の高血糖症の発症におけるグルカゴンの役割を調査する.
- グルカゴンを抑制することで,実験的な糖尿病モデルの高血糖症を改善できるかどうかを判断する.
- 糖尿病の治療戦略としてグルカゴン抗体の可能性を調査する.
主な方法:
- ソマトスタチン,アロキサン,または全臓切除術を用いた犬におけるインスリン欠乏症の誘導.
- 固有のグルカゴン分泌を抑制するためにソマトスタチンを投与する.
- 血糖値のモニタリングと高血糖症の重度の評価.
主要な成果:
- ソマトスタチンによるグルカゴンの抑制は,すべてのインスリン欠乏症モデルにおいて,高血糖症を著しく減少させ,または廃止した.
- 臓または消化器系からのグルカゴンの存在は,重度の高血糖症の発症に決定的でした.
- グルカゴンなしのインスリン不足だけでは,同じ程度の高血糖症にはつながらなかった.
結論:
- グルカゴンは,インスリン欠乏症とともに,重度の糖尿病性高血糖症の発症に必要な成分です.
- グルカゴンの抑制は,糖尿病におけるグルコースコントロールを改善するための有望な治療目標を提供します.
- グルカゴンの分泌または作用をターゲットにすることで,糖尿病患者のグルコース調節戦略を向上させることができます.
関連する概念動画
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

